$ORIB
Orion Bliss Corp.

2024 Q1 Form 10-Q Financial Statement

#000168316824000890 Filed on February 13, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q4 2023 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses
YoY Change
Operating Profit -$7.263K -$4.003K -$6.674K
YoY Change 8.83% -27.5%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income
YoY Change
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.263K -$4.003K -$6.674K
YoY Change 8.83% -27.5% 22.37%
Net Earnings / Revenue
Basic Earnings Per Share $0.00 $0.00 $0.00
Diluted Earnings Per Share $0.00 $0.00 $0.00
COMMON SHARES
Basic Shares Outstanding 3.038M shares 3.038M shares 2.975M shares
Diluted Shares Outstanding 3.038M shares 3.038M shares 2.975M shares

Balance Sheet

Concept 2024 Q1 2023 Q4 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $140.00 $782.00 $13.74K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $274.00 $916.00 $13.87K
YoY Change -98.02% -93.7%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets
YoY Change
TOTAL ASSETS
Total Short-Term Assets $274.00 $916.00 $13.87K
Total Long-Term Assets
Total Assets
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $82.00K $75.38K $41.75K
YoY Change 96.4% 94.52%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $82.00K $75.38K $41.75K
Total Long-Term Liabilities
Total Liabilities
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$102.7K -$95.42K -$48.84K
YoY Change 110.24% 126.29%
Common Stock $304.00 $304.00 $304.00
YoY Change 0.0% 5.19%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$81.73K -$74.46K -$27.88K
YoY Change
Total Liabilities & Shareholders Equity $274.00 $916.00 $13.87K
YoY Change -98.02% -93.7%

Cashflow Statement

Concept 2024 Q1 2023 Q4 2023 Q1
OPERATING ACTIVITIES
Net Income -$7.263K -$4.003K -$6.674K
YoY Change 8.83% -27.5% 22.37%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities
YoY Change
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities
YoY Change
NET CHANGE
Cash From Operating Activities
Cash From Investing Activities
Cash From Financing Activities
Net Change In Cash
YoY Change
FREE CASH FLOW
Cash From Operating Activities
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--04-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001854183
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
usd
CY2024Q1 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-01-31
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
333-257326
dei Entity Registrant Name
EntityRegistrantName
ORION BLISS CORP.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1591444
dei Entity Address City Or Town
EntityAddressCityOrTown
Ashdod
dei Entity Address Address Line1
EntityAddressAddressLine1
Kalonite 9-57
dei Entity Address Country
EntityAddressCountry
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
7724233
dei City Area Code
CityAreaCode
849
dei Local Phone Number
LocalPhoneNumber
8593819
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
true
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3038000 shares
CY2024Q1 us-gaap Cash
Cash
140 usd
CY2023Q2 us-gaap Cash
Cash
7781 usd
CY2024Q1 NONE Website Development Net
WebsiteDevelopmentNet
134 usd
CY2023Q2 NONE Website Development Net
WebsiteDevelopmentNet
134 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
274 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
7915 usd
CY2024Q1 NONE Accounts Payable Related Party
AccountsPayableRelatedParty
34000 usd
CY2023Q2 NONE Accounts Payable Related Party
AccountsPayableRelatedParty
25000 usd
CY2024Q1 NONE Due To Director
DueToDirector
48000 usd
CY2023Q2 NONE Due To Director
DueToDirector
19752 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
82000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
44752 usd
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3038000 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
304 usd
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
304 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20656 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
20656 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102686 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57797 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-81726 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-36837 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
274 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7915 usd
CY2024Q1 us-gaap Revenues
Revenues
0 usd
CY2023Q1 us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
0 usd
us-gaap Revenues
Revenues
600 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7263 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6674 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
44889 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
20828 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7263 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-6674 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-44889 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-20228 usd
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-7263 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6674 usd
us-gaap Net Income Loss
NetIncomeLoss
-44889 usd
us-gaap Net Income Loss
NetIncomeLoss
-20228 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.00
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.00
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2975304 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2975304 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3038000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3038000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2464111 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2464111 shares
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
0 usd
CY2021Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
200 usd
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-1925 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-1725 usd
CY2022 us-gaap Profit Loss
ProfitLoss
-26690 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-28415 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1310 usd
CY2022Q3 us-gaap Profit Loss
ProfitLoss
-8636 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-35741 usd
CY2022Q4 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
16450 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
-5521 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-24209 usd
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-6674 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-27883 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-8954 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-36837 usd
CY2023Q3 us-gaap Profit Loss
ProfitLoss
-33623 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-70460 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-4003 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-74463 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-7263 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-81726 usd
us-gaap Net Income Loss
NetIncomeLoss
-44889 usd
us-gaap Net Income Loss
NetIncomeLoss
-20228 usd
NONE Increase Decrease In Website Development
IncreaseDecreaseInWebsiteDevelopment
-0 usd
NONE Increase Decrease In Website Development
IncreaseDecreaseInWebsiteDevelopment
-0 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-44889 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20228 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
20760 usd
NONE Proceeds From Accounts Payable Related Party
ProceedsFromAccountsPayableRelatedParty
9000 usd
NONE Proceeds From Accounts Payable Related Party
ProceedsFromAccountsPayableRelatedParty
9000 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
28248 usd
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
4203 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37248 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33963 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7641 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
13735 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7781 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
140 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13735 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Interest Paid Net
InterestPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0 usd
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zX6grnUtk0f7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b><i>Financial Statement Reclassification</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain account balances from prior periods have been reclassified in these financial statements to conform to current period classifications.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-102686 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-57797 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84B_eus-gaap--UseOfEstimates_zrdHkQK231tj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Use of Estimates</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0 shares
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_zTqiFaLEADhe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b><i>Risks and Uncertainties</i></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In December 2020, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China. While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The ultimate impact of the COVID-19 pandemic on the Company’s operations is unknown and will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the COVID-19 outbreak, new information which may emerge concerning the severity of the COVID-19 pandemic, and any additional preventative and protective actions that governments, or the Company, may direct, which may result in an extended period of continued business disruption, reduced customer traffic and reduced operations. Any resulting financial impact cannot be reasonably estimated at this time but is anticipated to have a material adverse impact on our business, financial condition and results of operations.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Management expects that its business will be impacted to some degree, but the significance of the impact of the COVID-19 outbreak on the Company’s business and the duration for which it may have an impact cannot be determined at this time.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
75000000 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3038000 shares
us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-1525 usd
us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
1525 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2024Q1 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21564 usd
CY2024Q1 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
21564 usd
CY2024Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
102686 usd

Files In Submission

Name View Source Status
0001683168-24-000890-index-headers.html Edgar Link pending
0001683168-24-000890-index.html Edgar Link pending
0001683168-24-000890.txt Edgar Link pending
0001683168-24-000890-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
none-20240131.xsd Edgar Link pending
obliss_ex3101.htm Edgar Link pending
obliss_ex3201.htm Edgar Link pending
orion_i10q-13124.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
none-20240131_cal.xml Edgar Link unprocessable
none-20240131_def.xml Edgar Link unprocessable
none-20240131_pre.xml Edgar Link unprocessable
none-20240131_lab.xml Edgar Link unprocessable
orion_i10q-13124_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable